Insidious-onset, non-wheezing carteolol-induced asthma in an atopic patient without asthma history.
Jo-Hsuan WuJih-Shuin JerngChien-Chia SuPublished in: BMJ case reports (2019)
Carteolol, a non-selective beta-antagonist with a potential risk of severe bronchial constriction in patients with asthma, is one of the most commonly prescribed medication for managing ocular pressure in glaucoma. We present a case of a 24-year-old woman with a history of atopy but no known asthma who presented an insidious onset of clinical manifestations compatible with drug-induced asthma after the initiation of carteolol for ocular hypertension control. The patient developed progressive chest tightness and dyspnoea for 2 months before the pulmonary function test revealed a positive bronchoprovocation response. She reported significant improvement of respiratory symptoms within 2 weeks after the discontinuation of carteolol, and a negative provocation response was later confirmed by repeat pulmonary function test. In conclusion, eye drops with non-selective beta-antagonising effect can induce asthmatic symptoms in patients without a previous diagnosis of asthma and should be administered with caution in patients with associated risk factors.
Keyphrases
- lung function
- chronic obstructive pulmonary disease
- drug induced
- allergic rhinitis
- liver injury
- multiple sclerosis
- end stage renal disease
- blood pressure
- ejection fraction
- cystic fibrosis
- emergency department
- risk assessment
- spinal cord injury
- chronic kidney disease
- single cell
- early onset
- depressive symptoms
- peritoneal dialysis
- electronic health record
- optical coherence tomography